Literature DB >> 20948925

Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.

Sang Hyun Yoon1, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha.   

Abstract

The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.

Entities:  

Keywords:  Renal cell carcinoma; Renal dialysis; Sunitinib

Year:  2010        PMID： 20948925      PMCID： PMC2953783          DOI： 10.4143/crt.2010.42.3.180

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN： 1598-2998            Impact factor:   4.679


  12 in total

Review 1.  Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.

Authors:  N Janus; J Thariat; H Boulanger; G Deray; V Launay-Vacher
Journal:  Ann Oncol       Date:  2010-01-29       Impact factor: 32.976

2.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

3.  Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Authors:  Robert J Motzer; Gary R Hudes; Brendan D Curti; David F McDermott; Bernard J Escudier; Sylvie Negrier; Brigitte Duclos; Laurence Moore; Timothy O'Toole; Joseph P Boni; Janice P Dutcher
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

4.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

Review 5.  Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis.

Authors:  M D Hughson; D Buchwald; M Fox
Journal:  Arch Pathol Lab Med       Date:  1986-07       Impact factor: 5.534

6.  Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation.

Authors:  Ramón Peces; Jorge Martínez-Ara; José Luis Miguel; Javier Arrieta; Olga Costero; José Luis Górriz; Mari-Luz Picazo; Manuel Fresno
Journal:  Nephrol Dial Transplant       Date:  2004-08-17       Impact factor: 5.992

7.  Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea.

Authors:  Min Hee Hong; Hyo Song Kim; Chan Kim; Jung Ryun Ahn; Hong Jae Chon; Sang-Joon Shin; Joong-Bae Ahn; Hyun Cheol Chung; Sun Young Rha
Journal:  Cancer Res Treat       Date:  2009-06-30       Impact factor: 4.679

8.  Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.

Authors:  Chi Young Park
Journal:  Anticancer Drugs       Date:  2009-10       Impact factor: 2.248

9.  Sunitinib efficacy against advanced renal cell carcinoma.

Authors:  Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

10.  Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.

Authors:  Stefan Zastrow; Michael Froehner; Ivan Platzek; Vladimir Novotny; Manfred P Wirth
Journal:  Urology       Date:  2009-01-23       Impact factor: 2.649
View more
  3 in total

Review 1.  Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.

Authors:  Daniele Minardi; Luigi Quaresima; Matteo Santoni; Maristella Bianconi; Mario Scartozzi; Stefano Cascinu; Giovanni Muzzonigro
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

2.  Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

Authors:  Ibrahim Yildiz; Fatma Sen; Leyla Kilic; Rumeysa Ciftci; Mert Basaran
Journal:  Korean J Urol       Date:  2014-01-15

Review 3.  Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.

Authors:  Sungkyoung Kim; Wenping Ding; Lian Zhang; Wei Tian; Siyu Chen
Journal:  Onco Targets Ther       Date:  2014-05-12       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.